Patients
death, allergies, neutropenic colon, ALL
SECONDARY, COMPLICATIONS, ALLERGIES
We included 72 children with ALL at the Pediatric Hospital of the National Medical Center XXI Century IMSS, National Medical Center, and at the “Gaudencio González Garza” General Hospital, of the “La Raza” National Medical Center. Eligibility criteria were children newly diagnosed with ALL (established according to bone marrow aspirate, immunophenotyping, and immunohistochemistry) at the start of their chemotherapy treatment. Children who had previously been treated with chemotherapy in another institution, those with severe comorbidities, using corticosteroids, taking fish oil supplements during the previous weeks, who were unable to swallow ω3-LCPUFA or placebo capsules, and those who reported allergies to fish intake were excluded. From 72 children with ALL, in this secondary analysis, only 34 children were included (placebo group: 20 patients; ω3-LCPUFA group: 14 patients), due to participants dropping out for different reasons, such as discontinued intervention, death, clinical complications (neutropenic colon), or lack of adherence. We have reported this information in the manuscript of a clinical trial on body composition and omega 3 in children with ALL (currently under review by Clinical Nutrition ID YCLNU-D-23-00112).